IL155944A0 - INHIBITION OF Nf-Kb BY TRITERPENE COMPOSITIONS - Google Patents

INHIBITION OF Nf-Kb BY TRITERPENE COMPOSITIONS

Info

Publication number
IL155944A0
IL155944A0 IL15594401A IL15594401A IL155944A0 IL 155944 A0 IL155944 A0 IL 155944A0 IL 15594401 A IL15594401 A IL 15594401A IL 15594401 A IL15594401 A IL 15594401A IL 155944 A0 IL155944 A0 IL 155944A0
Authority
IL
Israel
Prior art keywords
inhibition
triterpene compositions
triterpene
compositions
Prior art date
Application number
IL15594401A
Other languages
English (en)
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of IL155944A0 publication Critical patent/IL155944A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
IL15594401A 2000-11-17 2001-11-19 INHIBITION OF Nf-Kb BY TRITERPENE COMPOSITIONS IL155944A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24971000P 2000-11-17 2000-11-17
US32285901P 2001-09-17 2001-09-17
PCT/US2001/043286 WO2002055016A2 (en) 2000-11-17 2001-11-19 INHIBITION OF NF-λB BY TRITERPENE COMPOSITIONS

Publications (1)

Publication Number Publication Date
IL155944A0 true IL155944A0 (en) 2003-12-23

Family

ID=26940287

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15594401A IL155944A0 (en) 2000-11-17 2001-11-19 INHIBITION OF Nf-Kb BY TRITERPENE COMPOSITIONS

Country Status (10)

Country Link
US (1) US20060148732A1 (xx)
EP (1) EP1355642A4 (xx)
JP (1) JP2004517131A (xx)
KR (1) KR100873828B1 (xx)
CN (1) CN1496255A (xx)
AU (1) AU2002245022B8 (xx)
CA (1) CA2429177A1 (xx)
IL (1) IL155944A0 (xx)
NZ (1) NZ525922A (xx)
WO (1) WO2002055016A2 (xx)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002322076A (ja) * 2001-02-26 2002-11-08 Oji Paper Co Ltd トリプシン阻害剤
US20060293388A1 (en) * 2003-10-02 2006-12-28 Universidade Federal Do Rio De Janeiro Pomolic acid, its isomers, derivatives and their uses, pharmaceutical composition, method to prepare the pharmaceutical composition and method for treating multidrug resistant tumours
JP2005194246A (ja) * 2004-01-09 2005-07-21 Ichimaru Pharcos Co Ltd ＮＦ−κＢ活性化抑制剤
CA2595749A1 (en) * 2005-01-27 2006-08-03 Research Development Foundation Combination therapy with triterpenoid compounds and proteasome inhibitors
US9284274B2 (en) 2005-12-07 2016-03-15 Ramot At Tel-Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
WO2008069342A1 (ja) * 2006-12-05 2008-06-12 Incorporated Administrative Agency National Agriculture And Food Research Organization アレルゲン性又は抗アレルギー性判定用プローブ
WO2008103916A2 (en) * 2007-02-23 2008-08-28 The Trustees Of Columbia Univeristy In The City Of New York Compositions and methods for treating cancer or a neurotrophic disorder
WO2008109717A1 (en) * 2007-03-05 2008-09-12 Rutgers, The State University Of New Jersey Compositions and methods for treating cancer
US10045951B2 (en) 2007-05-25 2018-08-14 The Trustees Of The University Of Pennsylvania Flaxseed lignan complex and its use thereof
WO2008147563A1 (en) * 2007-05-25 2008-12-04 The Trustees Of The University Of Pennsylvania Flaxseed lignan complex, methods of using and compositions thereof
EP2222339A2 (en) * 2007-11-26 2010-09-01 Research Development Foundation Use of avicins to deliver therapeutic and diagnostic agents
KR101014262B1 (ko) * 2008-12-11 2011-02-16 한국철도기술연구원 철도차량의 배장 장치
AU2010258223B2 (en) * 2009-06-09 2014-12-04 Ramot At Tel-Aviv University Ltd. Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
US9284252B2 (en) 2009-06-09 2016-03-15 Sepal Pharma Ltd. Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
JP5549908B2 (ja) * 2009-07-23 2014-07-16 国立大学法人 長崎大学 損傷ｄｎａ修復物質のスクリーニング方法
JP2013518595A (ja) * 2010-02-05 2013-05-23 ザ プロクター アンド ギャンブル カンパニー 化粧品スキンケア製剤における抗酸化効果のための作用物質を同定及び評価するための転写プロファイリング及びバイオマーカーに基づく方法
CN102370678A (zh) * 2010-08-18 2012-03-14 广州加原医药科技有限公司 积雪草在制备促进排铅作用药品或保健品的用途
CN103189046B (zh) 2010-09-09 2016-09-07 玫琳凯有限公司 包含植物提取物的局部护肤制剂
EP2433629B1 (en) * 2010-09-22 2017-11-08 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Use of boswellic acids for the prophylaxis and/or treatment of damages and/or inflammation of the islets of Langerhans
CN102580092A (zh) * 2011-01-13 2012-07-18 中国科学院上海生命科学研究院 泵铁蛋白的调控及其应用
US10018631B2 (en) 2011-03-17 2018-07-10 Cernostics, Inc. Systems and compositions for diagnosing Barrett's esophagus and methods of using the same
WO2012130481A1 (en) 2011-03-30 2012-10-04 Koc Universitesi INHIBITION OF NF-kB ACTIVITY BY TRITERPENE COMPOUNDS
CN102911241A (zh) * 2011-08-02 2013-02-06 苏州宝泽堂医药科技有限公司 从土贝母中制备贝萼皂苷元的方法
WO2013126730A1 (en) 2012-02-24 2013-08-29 Research Development Foundation Derivatives of avicin d and methods of making and using thereof
MX2014010312A (es) * 2012-02-27 2015-04-14 Del Mar Pharmaceuticals Metodos analiticos mejorados para analizar y determinar impurezas en dianhidrogalactitol.
RU2525426C2 (ru) * 2012-07-16 2014-08-10 Государственное научное учреждение Научно-исследовательский ветеринарный институт Нечерноземной зоны Российской Федерации Российской академии сельскохозяйственных наук Способ коррекции вторичных иммунодефицитов у телят
US20150182488A1 (en) 2012-09-11 2015-07-02 Olatec Industries Llc Methods for treating inflammation and pain
WO2015017280A1 (en) * 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
MX2016006457A (es) * 2013-11-18 2017-01-06 Del Mar Pharmaceuticals Analisis de cromatografia liquida de alto rendimiento (hplc) de impurezas en dianhidrogalactitol.
CN104147015B (zh) * 2014-06-27 2016-05-25 孙蕾 闭花木酮Cleistanone的二乙胺衍生物在制备抗慢性阻塞性肺病药物中的应用
CN105797154B (zh) * 2014-12-31 2020-03-10 中国科学院上海生命科学研究院 软骨干细胞的分离及其应用
WO2018089539A1 (en) 2016-11-08 2018-05-17 Reata Pharmaceuticals, Inc. Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
WO2019012159A1 (en) 2017-07-14 2019-01-17 Protea Biopharma N.V. METHODS AND MEANS FOR DIAGNOSING AND / OR TREATING A FATIGUE-ASSOCIATED DISEASE
CN111479574B (zh) * 2017-12-15 2024-02-09 澳大利亚国立大学 用于治疗和预防细胞外组蛋白介导的病理的化合物
CN109134618B (zh) * 2018-09-04 2021-12-28 广西壮族自治区中国科学院广西植物研究所 茜草科类型环肽二糖苷及其制备方法和应用
CN109876004A (zh) * 2019-04-25 2019-06-14 上海中医药大学 柴胡皂苷a的新用途
US20240024220A1 (en) * 2019-05-11 2024-01-25 Youngsuk Yi Neurotoxin compositions and methods
CN110563792A (zh) * 2019-09-09 2019-12-13 南开大学 G蛋白偶联胆汁酸受体激动剂及其应用
CN110731965A (zh) * 2019-11-11 2020-01-31 西安交通大学 柴胡皂苷a在制备防治银屑病的药物中的应用
CN113018302B (zh) * 2021-04-01 2023-09-05 河南中医药大学 一种薯蓣皂苷元衍生物与dha自组装纳米粒的制备方法及应用
CN115505021B (zh) * 2021-06-23 2023-08-15 沈阳药科大学 具有炎症性肠病治疗作用的乌苏酸衍生物及其制备方法和用途
CN115505020B (zh) * 2021-06-23 2023-09-12 沈阳药科大学 乌苏酸皂苷及其制备方法和用途
CN113671066B (zh) * 2021-07-26 2023-02-24 广西中医药大学 粉团蔷薇根药材的质量控制方法
CN115894601B (zh) * 2021-09-30 2024-07-26 山东新时代药业有限公司 一种10,19-开环环阿屯烷三萜ii及其制备方法和应用
CN115894595B (zh) * 2021-09-30 2024-04-30 山东新时代药业有限公司 一种10,19-开环环阿屯烷三萜i及其制备方法和应用
CN115197932A (zh) * 2022-09-02 2022-10-18 沈阳农业大学 一种皮脂酸修饰的磁性纳米颗粒的制备及其固定化β-葡萄糖苷酶

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3070623A (en) * 1957-07-16 1962-12-25 Biorex Laboratories Ltd Pharmacological compounds
US3070624A (en) * 1960-03-04 1962-12-25 Biorex Laboratories Ltd Glycyrrhetinic acid dialkylaminoalkyl esters
FR2378044A1 (fr) * 1977-01-20 1978-08-18 Sarget Lab Nouvel extrait vegetal a partir de varietes de chrysanthellum
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4452901A (en) * 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4526714A (en) * 1982-12-13 1985-07-02 Cordis Europa N.V. Conjugates of anticoagulant and protein
US5221605A (en) * 1984-10-31 1993-06-22 Igen, Inc. Luminescent metal chelate labels and means for detection
US5238808A (en) * 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US5310687A (en) * 1984-10-31 1994-05-10 Igen, Inc. Luminescent metal chelate labels and means for detection
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US4975369A (en) * 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US5183756A (en) * 1988-08-19 1993-02-02 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibody (D612) having selective reactivity for gastrointestinal caricinomas and method for employing the same
US5242813A (en) * 1990-10-12 1993-09-07 The United States Of America As Represented By The Department Of Health And Human Services Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors
KR100291620B1 (ko) * 1992-09-29 2001-10-24 추후제출 부갑상선호르몬의활성단편의폐를통한전달방법
KR0164266B1 (ko) * 1996-02-22 1999-01-15 오오니시 쿠니히로 인삼사포닌 장내세균 대사물 및 이를 유효성분으로하는 제암제제
US5908861A (en) * 1997-05-13 1999-06-01 Octamer, Inc. Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US5965421A (en) * 1997-11-26 1999-10-12 Human Genome Sciences, Inc. Human IRAK-2
AU1573499A (en) * 1997-12-23 1999-07-19 Moser, Rene Sesquiterpene lactones specifically inhibit activation of nf-k B by preventing the degradation of IkB-alpha and IkB-beta
WO1999059578A1 (en) * 1998-05-19 1999-11-25 Research Development Foundation Triterpene compositions and methods for use thereof
HUP0102492A2 (hu) * 1998-06-19 2001-11-28 Smithkline Beecham Corp. Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására

Also Published As

Publication number Publication date
WO2002055016A3 (en) 2003-09-04
EP1355642A4 (en) 2007-04-04
CA2429177A1 (en) 2002-07-18
NZ525922A (en) 2005-05-27
CN1496255A (zh) 2004-05-12
EP1355642A2 (en) 2003-10-29
KR20030070034A (ko) 2003-08-27
KR100873828B1 (ko) 2008-12-15
AU2002245022B8 (en) 2006-10-12
WO2002055016A2 (en) 2002-07-18
US20060148732A1 (en) 2006-07-06
AU2002245022B2 (en) 2006-09-21
JP2004517131A (ja) 2004-06-10

Similar Documents

Publication Publication Date Title
IL155944A0 (en) INHIBITION OF Nf-Kb BY TRITERPENE COMPOSITIONS
AU7174101A (en) Pharmaceutical compositions of estrogenic agents
PH12001001603B1 (en) Cleansing compositions
AU2001247690A1 (en) Sterol ester compositions
AU2002213002A1 (en) Antisense inhibition of caspase 6 expression
AU6093101A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2001268659A1 (en) Water treatment compositions
HK1055442A1 (en) Branched primary alcohol compositions and derivatives thereof
GB9927315D0 (en) Inhibitor compositions
EP1320385A4 (en) COMBINATION COMPOSITIONS
NZ524418A (en) Highly purified simvastatin compositions
GB0019651D0 (en) Compositions
ZA200303623B (en) Inhibition of NF-kB triterpene compositions
HK1061978A1 (en) Lipid peroxide-lowering compositions
GB0004518D0 (en) Compositions
AU2000275584A1 (en) Anticancer compositions
AU6650901A (en) Composition for inhibiting feeding of weevils
AU2911200A (en) Lavatory cleansing compositions
AU2001242761A1 (en) Anticancer compositions
AU8254101A (en) Medicinal compositions
GB0018502D0 (en) New compositions of matter
GB0004522D0 (en) Compositions
AU3625701A (en) Surface-active compositions
GB0013615D0 (en) Compositions
GB0017288D0 (en) Compositions